Each model exhibits distinct pathological mechanisms, including variations in Aβ deposition, tau pathology, neuroinflammation, and metabolic dysfunction, which can lead to inconsistencies in study outcomes when assessing the impact of obesity and systemic inflammation on AD progression. This evidence concerns the gene MAPT and Obesity.